On June 30, 2023 Imugene Limited (ASX: IMU), a clinical stage immunooncology company, reported new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona (Press release, Imugene, JUN 30, 2023, View Source [SID1234632980]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract Title: HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER-2-targeting peptide vaccine plus SOC chemotherapy in patients with HER-2+ advanced stomach Cancer — Correlation of the antibody responses and clinical outcome.
Session Title: Basic Gastric Cancer – Biomarkers and Translational Research.
Session Number: Poster Discussion D-8.
Presentation Session: 29 June 2023, 9:30 am – 5:40 pm CEST.
Presenting Author: Dr Joshua Tobias, Medical University of Vienna, Vienna, Austria.
Conclusions drawn from the study include;
• HER-Vaxx treatment produced robust anti-HER-2-IgG* and IgG1 antibody responses (p<0.001).
• HER-Vaxx-based vaccination of patients with HER-2 overexpressing gastric/gastro-esophageal junction cancer (GC) induced anti-HER-2-IgG and IgG1 subclass antibody responses (p<0.001).
• HER-Vaxx induced antibodies correlated with tumour reduction (p=0.001) • Compared to chemotherapy alone, the vaccination resulted in a statistically significant overall survival benefit.
• The present data further validate the proof of concept for a first-in-class B-cell immunotherapy based on HER-2/neu peptides.
* IgG-Immunoglobulin G is a type of antibody. Representing approximately 75% of serum antibodies in humans, IgG is the most common type of antibody found in blood circulation.
For 25 years, the World Congress on Gastrointestinal Cancer has been the foundation for sharing the most advanced research and innovations impacting the field of Gastrointestinal Cancer.
As the largest global gathering in the field, the Congress brings together leading gastroenterology, oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe to share pioneering research, approaches, and best practices in treating patients with cancers of the gastrointestinal tract.